...
NVOLARGE

Novo Nordisk A/S

HealthcareDrug Manufacturers - General
$37.45
$0.00(-0.45%)
52W$37.31
$91.90
FinancialsValuationvs ABBV
Updated Mar 2, 12:00 AM
RSI24
RS Rating13/99
Beta1.08
Volatility55%
F-Score5/9
Mkt Cap$126.3B
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

Novo Nordisk A/S is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 13), showing significant lag compared to the market leaders. Earnings contraction of 5% provides fundamental context to the price action. However, RSI is deeply oversold at 24, suggesting potential for a mean-reversion bounce.

Relative Strength
13
out of 99
Lagging
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
1.08
vs S&P 500
MARKET
52W Position
0%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$52.55
50 SMA > 100 SMA$51.63
100 SMA > 150 SMA$52.74
150 SMA > 200 SMA$57.15

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$46.91-20.17%BELOW
50 SMA$52.55-28.74%BELOW
100 SMA$51.63-27.46%BELOW
150 SMA$52.74-29.00%BELOW
200 SMA$57.15-34.47%BELOW

Price Performance

1D-0.5%
1W-5.5%
1M-37.9%
3M-24.1%
6M-33.3%
YTD-28.5%
1Y-58.7%
3Y-19.0%
52-Week Trading Range0% from low
$37.45
52W Low$37.31
52W High$91.90

Technical Indicators

RSI (14)OVERSOLD
23.7
305070
VCP ScoreCOOL
5/10
Base depth: 71.7%

Risk Profile

Beta
1.08
52W Vol
55%
ATR
$1.74
Max DD (1Y)
-59%

Volume Analysis

Today
37
50D Avg
20.25M
Vol Ratio
0.00x
Liquidity
VERY LIQUID

Earnings Momentum

Q1'25+15%
$6.53
Q2'25+33%
$5.96
Q3'25-26%
$4.50
Q4'25-5%
$6.04
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+10.66%
5 Years:+18.55%
3 Years:+18.87%
TTM:+2.34%

Compounded Profit Growth

10 Years:+13.04%
5 Years:+20.65%
3 Years:+23.52%
TTM:+1.81%

Stock Price CAGR

10 Years:+3.84%
5 Years:+0.56%
3 Years:-19.01%
1 Year:-58.69%

Return on Equity

10Y Avg:122.6%
5Y Avg:83.4%
3Y Avg:75.7%
Last Year:50.8%

Key Metrics

Market Cap$126.3B
Gross Margin81.0%
Net Margin33.1%
Piotroski F-Score5/9

More NVO Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

NVO vs ABBVABBVAMGNGILDBIIB

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 13 meansNVO outperformed 13% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.08 means 8% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is NVO in an uptrend right now?

NVO has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is NVO overbought or oversold?

NVO's RSI (14) is 24. The stock is oversold (RSI < 30), which could indicate a bounce opportunity.

Is NVO outperforming the market?

NVO has a Relative Strength (RS) Rating of 13 out of 99. NVO is currently lagging the broader market.

Where is NVO in its 52-week range?

NVO is trading at $37.45, which is 41% of its 52-week high ($91.90) and 0% above its 52-week low ($37.31).

How volatile is NVO?

NVO has a Beta of 1.08 and 52-week volatility of 55%. It's more volatile than the S&P 500 - expect bigger swings.